The objective of this work was to investigate the effect of Ligilactobacillus salivarius MP101 on the functional (Barthel index), cognitive (GDS/FAST) and nutritional (MNA) status, and on the nasal and fecal inflammatory profiles of elderly living in a nursing home highly affected by COVID-19.

开始日期2020-10-01

申办/合作机构

Universidad Complutense de Madrid

100 项与 Oleoyl-estrone 相关的临床结果

登录后查看更多信息

100 项与 Oleoyl-estrone 相关的转化医学

登录后查看更多信息

100 项与 Oleoyl-estrone 相关的专利（医药）

登录后查看更多信息

300

项与 Oleoyl-estrone 相关的文献（医药）

2024-09-01·Food Research International

Effects of fatty acids and glycerides on the structure, cooking quality, and in vitro starch digestibility of extruded buckwheat noodles

Article

作者: Wu, Di ; Wang, Zhenjiong ; Yu, Menglan ; Gao, Chengcheng ; Cheng, Weiwei ; Meng, Linghan ; Tang, Peiqi ; Feng, Xiao ; Zhang, Shuyi ; Tang, Xiaozhi

This study aimed to explore the effects of various lipids on the structure, cooking quality, and in vitro starch digestibility of extruded buckwheat noodles (EBNs) with and without 20% high-amylose corn starch (HACS). Fourier transform infrared spectroscopy, differential scanning calorimetry, and X-ray diffraction revealed that lauric acid bound more strongly to starch than did stearic acid and oleic acid, and the binding capacity of fatty acids with starch was stronger than that of glycerides. The presence of HACS during extrusion facilitated increased formation of starch-lipid complexes. Evaluations of cooking quality and digestion characteristics showed that EBNs containing 20% HACS and 0.5% glycerol monooleate demonstrated the lowest cooking loss (7.28%), and that with 20% HACS and 0.5% oleic acid displayed the lowest predicted glycemic index (pGI) (63.54) and highest resistant starch (RS) content (51.64%). However, excessive starch-lipid complexes were detrimental to EBNs cooking quality and the resistance of starch to digestive enzymes because of the damage to the continuity of the starch gel network. This study establishes a fundamental basis for the development of EBNs with superior cooking quality and a relatively lower GI.

2024-06-01·Food Chemistry

Optimization and characterization of chestnut shell pigment extract obtained microwave assisted extraction by response surface methodology

Article

作者: Suna, Senem ; Cavus, Semra ; Uysal, Erdinc ; Kocer, Serhat ; Utku Copur, Omer ; Ece Tamer, Canan ; Kayahan, Seda ; Akman, Ozgur

The objective of this study is to find optimum conditions to valorize chestnut shell bioactive compounds with coloring pigments through microwave-assisted extraction. With this aim, response surface methodology with central composite design was used. Microwave power (800 W), extraction time (12 min) and solvent concentration (NaOH: 0.115 mol/L) were determined as the optimum conditions to maximize the responses like color value, total phenolic content and total antioxidant capacity. In the optimized extract (OE), characterization of brown melanin like pigments were assessed by Spectrophotometer, Fourier Transform Infrared Spectrometer and major phenolics were identified as; gallic acid, ellagic acid, protocatechuic acid, catechin, and epicatechin as 0.53, 0.48, 0.46, 0.46, 0.14 mg/g dried weight (dw) by High Performance Liquid Chromatography, respectively. In terms of antibacterial activity, OE inhibited the growth of Staphylococcus aureus. Consequently, chestnut shells were successfully processed into natural coloring agents that were possessing strong brown color properties as well as high bioactive potential.

2024-05-01·European Journal of Pharmaceutics and Biopharmaceutics

Synthesis of folate targeted theranostic cubosomal platform for co-delivery of bismuth oxide and doxorubicin to melanoma in vitro and in vivo

Article

作者: Ramezani, Mohammad ; Alibolandi, Mona ; Zahiri, Mahsa ; Kamali, Hosein ; Mohammad Taghdisi, Seyed ; Nekooei, Negar ; Nekooei, Sirous ; Abnous, Khalil

Liquid crystalline nanoparticles (LCNPs) have gained much attention in cancer nanomedicines due to their unique features such as high surface area, storage stability, and sustained-release profile. In the current study, a novel LCNP for co-encapsulation of Bi₂O₃ and hydrophilic doxorubicin (DOX) was fabricated and functionalized with folic acid (FA) to achieve efficient tumor targeting toward CT-scan imaging and chemotherapy of melanoma in vitro and in vivo. LCNPs Bi₂O₃ NPs were prepared using glycerol monooleate-pluronic F-127 (GMO/PF127/water). Firstly, GMO/water were homogenized to prepare LC gel. Then, the stabilizer aqueous solution (PF127/Bi₂O₃/DOX) was added to the prepared LC gel and homogenized using homogenization and ultrasonication. The formulated NPs exhibited superior stability with encapsulation efficiency. High cytotoxicity and cellular internalization of the FA-Bi₂O₃-DOX-NPs were observed in comparison with Bi₂O₃-DOX-NPs and the free DOX in folate-receptor (FR) overexpressing cells (B₁₆F₁₀) in vitro. Moreover, ideal tumor suppression with increased survival rate were observed in tumorized mice treated with FA-Bi₂O₃-DOX-NPs compared to those treated with non-targeted one. On the other hand, the CT-imaging ability of the Bi₂O₃-DOX-NPs was tested inB₁₆F₁₀ tumor-bearing mice. The obtained data indicated a high potential of the developed targeted theranostic FA-Bi₂O₃-DOX-NPs for diagnostics and treatment of melanoma.

项与 Oleoyl-estrone 相关的新闻（医药）

2024-01-10

·Pharmaceutical Technology

EMA approves Mitochon’s neurogenerative disease study

Mitochon’s small molecule candidate MP101 modulates mitochondrial function to treat neurogenerative diseases. Credit: Solskin via Getty Images. The European Medicines Agency (EMA) has awarded approval to Mitochon Pharmaceuticals to initiate a Phase I/IIa biomarker study to treat patients with several neurogenerative diseases. The 14-day pilot study will investigate MP101, a small molecule orally administered drug which targets mitochondrial function. The clinical trial will enrol patients with amyotrophic lateral sclerosis (ALS), multiple sclerosis, Huntington’s disease, and Alzheimer’s disease, and evaluate the safety and potential changes in disease-specific biomarkers of the drug. Mitochon received orphan drug designation from the US Food and Drug Administration (FDA) for MP101 to treat Huntington’s disease and ALS, in 2019 and 2020, respectively. The candidate generated promising results in preclinical studies, with Mitochon reporting that MP101 indicated favourable pharmacological and biochemical responses. Data showed that MP-101 preserves brain volume, medium spiny neurons, general neurons and limb movement, as well as reducing seizure duration. According to GlobalData’s Pharma Intelligence Center, MP101 has been investigated in several clinical studies, including for optic neuritis, in normal healthy volunteers, and in Huntington’s disease patients. GlobalData is the parent company of Pharmaceutical Technology. In the announcement accompanying the approval, Mitochon’s co-founder and chief scientific officer (CSO) John Geisler said: “We are delighted for the opportunity to explore this provocative idea that most, if not all neurodegenerative diseases are rooted in mitochondrial dysfunction. We predict that chronic treatment with this unique platform, at micro-doses, will resolve mitochondrial issues and change important disease-specific biomarkers in all four indications similarly.” According to GlobalData’s Pharma Intelligence Center, Mitochon has another drug in its pipeline, MP201. The therapy modulates mitochondrial function, protecting the neurons through mitochondrial uncoupling, which prevents excessive ROS formation and oxidative damage. The candidate is also under development for the treatment of Parkinson’s disease, amyotrophic lateral sclerosis, and traumatic brain injury. In July 2023, InSilicoTrials and Axoltis teamed up to develop disease-modifying drugs for neurological disorders. Precision Biosciences filed a patent in September 2023 on a mitochondria-targeting engineered meganuclease for modifying human mitochondrial DNA.

孤儿药

2024-01-09

·Business Wire

European Medicines Agency (EMA) Greenlights Mitochon Pharmaceuticals to Initiate Phase I/IIa Biomarker Study in Neurodegenerative Diseases

BLUE BELL, Pa.--( BUSINESS WIRE )-- Mitochon Pharmaceuticals today announced that it was awarded approval from EMA to begin enrollment for a Phase I/IIa biomarker study in Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Huntington’s Disease (HD) and Alzheimer’s Disease (AD) participants. Mitochon’s MP101, a once-daily, oral brain penetrant mitochondrial stimulator, that improves central nervous system survival and function will be used in this 14-day pilot study. The aim of the study is to show safety in the target patient populations and demonstrate meaningful changes in disease specific biomarkers. Successful completion of this study will provide the basis for long term Phase IIb clinical studies in ALS, Secondary & Primary Progressive MS, HD, and AD patients, leading to the first mitochondrial specific therapy for these truly insidious diseases. “We are delighted for the opportunity to explore this provocative idea that most, if not all neurodegenerative diseases are rooted in mitochondrial dysfunction. We predict that chronic treatment with this unique platform, at micro-doses, will resolve mitochondrial issues and change important disease specific biomarkers in all four indications similarly,” said Dr. John G. Geisler, Ph.D., co-founder and CSO of Mitochon. MP101 and MP201 are mitochondrial targeted, once-a-day, oral therapies that have been shown to shield cells from damage caused by a host of degenerative processes (genetic and non-genetic, auto-immune and injury). In preclinical studies, these compounds have exhibited striking protective and functional benefits in disease models. Benefits include: brain volume sparing in Huntington’s disease; axonal protection from demyelination in Multiple Sclerosis, protection of neuromuscular junction in ALS, blocking the loss of short-term memory in Alzheimer’s, and protecting brain cells from traumatic brain injury (TBI) such as severe concussions. About Mitochon Pharmaceuticals Mitochon was founded in 2015 with the mission to develop treatments for insidious diseases through the modulation of mitochondrial physiology, with applications to neurodegeneration, neuromuscular, and neuro-trauma. Mitochon’s lead programs, MP101 and MP201, specifically harnesses the power of the mitochondria to provide broad neural protection (MOA: https://www.mitochonpharma.com/mechanism-of-action/ ). These compounds elicit mild increases in energy expenditure that result in strengthening cellular survival – similar to the positive effects seen with fasting and exercise. These compounds also induce an important neurotrophin, Brain Derived Neurotrophic Factor (BDNF), involved in cognition, growth and repair. Additional Information: www.mitochonpharma.com

临床2期

100 项与 Oleoyl-estrone 相关的药物交易

登录后查看更多信息